Stock Researching
FDA Approves Abraxane For Treatment Of Pancreatic Cancer
Stock Researching
Publish date: Tue, 10 Sep 2013, 09:59 AM
Stock Researching
0 241,468
Stockresearching is a blog designed to help the independent investor create new ideas and receive valuable informed information.
From Liston Street Pulse:
Abraxane in combination with gemcitabine was approved by the FDA on September 9, 2013 as a first-line treatment for late-stage metastatic pancreatic cancer. Earlier, in January this year, Celgene (CELG) had presented late stage clinical data at symposium of the American Society of Clinical Oncology. Data presented by the company demonstrated […]
The post FDA Approves Abraxane For Treatment Of Pancreatic Cancer appeared first on Liston Street Pulse.
More articles on Stock Researching
Enbridge Inc: 2016 Fundamental Analysis WACC, Cost of Debt and Cost of Equity $ENB
Created by Stock Researching | Dec 13, 2016
Apple Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $AAPL
Created by Stock Researching | Dec 04, 2016
Visa Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $V
Created by Stock Researching | Dec 02, 2016
Telus Corp. Cost of Debt, CAPM, WACC and Valuation $TU, $T.TO
Created by Stock Researching | Nov 19, 2016
Assessing Canadian Telecom Exposure, $BCE is worth a look
Created by Stock Researching | Nov 10, 2016
$UPS Deriving Value From E-Commerce Growth And Lower Energy Prices
Created by Stock Researching | Oct 05, 2015
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
3
CEO Morning Brief
4
CEO Morning Brief
Scaramucci Expects Bitcoin Record on Rate Cuts, Clearer US Rules
5
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
